Related Experiment Video
Updated: Jun 3, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults
Pouran Layegh1, Sara Rahsepar, Amir Ali Rahsepar
1Research Center for Skin Diseases and Cutaneous Leishmaniasis, Qaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Layeghpo@mums.ac.ir
Abstract:
Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (> 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis
Pharmacokinetics in Pediatric Patients: Drug Excretion
Rocky Mountain Spotted Fever
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

